Save time and jump to the most important pieces.
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today applauded the introduction of a Senate companion bill to H.R. 6373, the VA Spinal Trauma Access to New Devices (STAND) Act. The Senate companion bill was introduced by Chairman of the Senate Veterans' Affairs Committee, Senator Jon Tester (D-MT), and the Ranking Member of that committee, Senator Jerry Moran (R-KS).
Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that effective with the open of the market on Friday, March 15, 2024, the Company will complete a 1-for-7 reverse
Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy. Additional study demonstrates that the improvements in walking speed and distance following high-intensity gait training with the ReStore Exo-Suit were maintained by individuals post-stroke 4 weeks after the intervention had concluded. Combined results highlight the clinical value of the ReStore Exo-Suit and its related breakthrough propulsion-augmenting technologies within the Lifeward product development pipeline. MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, M
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 08, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) (the "Company" or "ReWalk"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced the appointment of Michael Lawless, CPA, as Chief Financial Officer, effective September 19, 2022. Mr. Lawless brings more than 20 years of experience leading finance and investor relations activities at life science and technology companies to drive greater financial discipline, better strategic decision making, and improved access to capital. "Mike brings an extensive background in strategic finance and investor relations
Shareholders Are Not Required to Take Action at This Time MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received notice from Creative Value Capital Limited Partnership ("CVC"), which claims to hold approximately 3% of ReWalk's outstanding shares, that it intends to nominate two candidates for election to the Company's Board of Directors (the "Board") and submit two additional proposals for consideration at the 2022 Annual Meeting of Shareholders (the "Annual
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, April 20, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics. Ltd. (NASDAQ:RWLK) ("ReWalk" or "The Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, announced today that the Board has approved the appointment of Joseph Turk, Jr. to the Board of Directors, effective today. After initiating his career at McKinsey and Company, Mr. Turk has assembled an extensive history in the medical device industry beginning with his role as Director of New Business Development at Boston Scientific. Subsequently, he held multiple roles at NxStage Medical, including President, where he led all commercialization
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
ReWalk Robotics, Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, announced the successful demonstration of a proof-of-concept next-generation exoskeleton. As part of the Israel Innovation Authority's MAGNET incentive program, the Human Robot Interaction Consortium (the "HRI Consortium"), the company has reached a milestone by integrating advanced sensing technologies and artificial intelligence ("AI") to enable autonomous decision making in the Company's latest exoskeleton prototype. "We have successfully demonstrated that by combining
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ReWalk Robotics (NASDAQ:RWLK) with a Buy and maintains $3 price target.
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
4 - ReWalk Robotics Ltd. (0001607962) (Issuer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
8-K - ReWalk Robotics Ltd. (0001607962) (Filer)
SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)
SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)
SC 13D - ReWalk Robotics Ltd. (0001607962) (Subject)
Highest quarterly and annual revenue in the history of LifewardCommercial and operational integration complete; synergiesexpected to yield $3 million in annual net savings MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced its financial results for the three months and full year ended December 31, 2023. Highlights of the Fourth Quarter of 2023 and Early 2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that the Company will release its fourth quarter and fiscal year-end 2023 financial results before the markets open on Tuesday, February 27, 2024. Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the f
Record Quarterly Revenue of $4.4 Million Successful Completion of AlterG Acquisition and Significant Progress of Integration Major Advancement in Efforts to Attain Medicare Payment Coverage of Exoskeletons MARLBOROUGH, Mass., BERLIN and YOKNEAM ILLIT, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced its financial results for the three and nine months ended September 30, 2023. Highlights of the Third Quarter of 2023 include: Closing of ReWalk's acquisition o
HC Wainwright reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously
HC Wainwright & Co. reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously